Eldridge Investment Advisors’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-5,783
Closed -$253K 130
2021
Q4
$253K Buy
+5,783
New +$274K 0.08% 113

Other funds holding IDNA

Eldridge Investment Advisors's IDNA Position: Q1 2022 in Review

Eldridge Investment Advisors sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q1 2022, closing a stake of 5,783 shares — an estimated $253K sold.

Eldridge Investment Advisors first reported a position in IDNA in Q4 2021 and held it in 1 quarter. The position peaked at $253K in Q4 2021. 86 funds tracked by Wall St. Rank hold IDNA as of Q1 2022.

  • Eldridge Investment Advisors reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q1 2022 after selling out during the quarter.
  • Eldridge Investment Advisors sold 5,783 iShares Genomics Immunology and Healthcare ETF shares in Q1 2022, an estimated $253K.
  • Eldridge Investment Advisors first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2021 and held it in 1 quarter.
  • Eldridge Investment Advisors's iShares Genomics Immunology and Healthcare ETF position peaked at $253K in Q4 2021.
  • 86 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2022.

Based on Eldridge Investment Advisors's 13F filing for Q1 2022, filed 10 May 2022.